Development of PEGylated aspartic acid modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-B-117-Tuesday
• By: YAMASHITA, Shugo (Kyoto Pharmaceutical University, Biopharmaceutics, Kyoto, Japan)
• Co-author(s): Shugo Yamashita: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Hidemasa Katsumi: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Nozomi Hibino: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Yugo Isobe: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Yumiko Yagi: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Yuka Tanaka: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Saki Yamada: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Kosuke Kusamori: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Toshiyasu Sakane: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Akira Yamamoto: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  
• Abstract:

  Backgrounds

  The number of bone metastasis patients has been rapidly increasing in association with the global population aging. However, most anticancer drugs do not have a high affinity for bone hydroxyapatite under physiological conditions. Therefore, development of bone targeting system is highly required for the treatment of bone metastasis. In ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login